NOX2-shRNA

NOX2-shRNA is a non-viral gene therapy candidate being developed by Inomagen Therapeutics for the treatment of atrial fibrillation (AF). The therapy utilizes short hairpin RNA (shRNA) delivered via a plasmid to knock down the expression of NADPH oxidase 2 (NOX2) in atrial tissue. NOX2-generated oxidative stress is a primary driver of electrical remodeling and the perpetuation of AF; by silencing this target, the therapy aims to address the underlying molecular mechanisms of the disease rather than just managing symptoms. The plasmid is delivered via targeted injection into the atrial tissue, followed by electroporation to facilitate gene delivery using the company's proprietary TRAVGE™ transvenous catheter system. In preclinical canine models, the therapy successfully prevented the onset of sustained AF for up to 12 weeks. The program is currently in IND-enabling studies.

Other names

NADPH oxidase 2 short hairpin RNANOX2 shRNANOX-2 shRNANOX 2 shRNANOX2 shRNA gene therapyNOX-2 shRNA gene therapyNOX 2 shRNA gene therapyNOX2-shRNA plasmidNOX-2-shRNA plasmidNOX 2-shRNA plasmid